A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

December 7, 2015

Primary Completion Date

December 9, 2016

Study Completion Date

December 9, 2016

Conditions
Influenza
Interventions
DRUG

Oseltamivir

75 mg capsules orally BID from Day 1 to Day 5.

DRUG

MEDI8852

MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.

DRUG

Placebo

Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.

Trial Locations (31)

2113

Research Site, Johannesburg

4001

Research Site, Durban

9400

Research Site, Winnie Mandela

9460

Research Site, Welkom

15478

Research Site, Smithfield

28150

Research Site, Shelby

28602

Research Site, Hickory

33012

Research Site, Hialeah

33013

Research Site, Hialeah

33014

Research Site, Miami Lakes

33016

Research Site, Hialeah

33162

Research Site, North Miami Beach

33165

Research Site, Miami

33173

Research Site, Miami

33185

Research Site, Miami

46123

Research Site, Avon

47304

Research Site, Muncie

48085

Research Site, Troy

59701

Research Site, Butte

70124

Research Site, New Orleans

78229

Research Site, San Antonio

84015

Research Site, Clinton

90017

Research Site, Los Angeles

90806

Research Site, Long Beach

91303

Research Site, Canoga Park

91786

Research Site, Upland

0087

Research Site, Pretoria

0157

Research Site, Pretoria

0181

Research Site, Pretoria

0183

Research Site, Pretoria

0380

Research Site, Thabazimbi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT02603952 - A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza | Biotech Hunter | Biotech Hunter